Valuation: Harvard Bioscience, Inc.

Market Cap 42.94M 38.91M 35.99M 32.47M 61.2M 4.05B 63.36M 434M 172M 2.16B 161M 158M 6.87B P/E 2026 *
-4.31x
P/E 2027 * -16.1x
Enterprise Value 42.94M 38.91M 35.99M 32.47M 61.2M 4.05B 63.36M 434M 172M 2.16B 161M 158M 6.87B EV / Sales 2026 *
0.48x
EV / Sales 2027 * 0.45x
Free-Float
90.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.37%
1 week+2.42%
Current month+4.61%
1 month+15.08%
3 months+43.23%
6 months+86.20%
Current year+39.20%
1 week 8.21
Extreme 8.2082
10.2
1 month 7.9
Extreme 7.9
10.2
Current year 4
Extreme 4
10.2
1 year 4
Extreme 4
10.2
3 years 2.81
Extreme 2.813
55.6
5 years 2.81
Extreme 2.813
78.4
10 years 2.81
Extreme 2.813
87.5
Manager TitleAgeSince
Chief Executive Officer 55 2025-07-27
Director of Finance/CFO 63 2025-05-11
Chief Tech/Sci/R&D Officer - 2019-03-31
Director TitleAgeSince
Director/Board Member 52 2017-10-23
Director/Board Member 55 2025-06-01
Director/Board Member 52 2025-07-15
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26 Free

Chief Executive Officer

75,000 0.1677%
3/20/26 Free

Chief Financial Officer

30,000 0.0671%
3/17/26 Buy

Director

10,000 0.0224%
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%+2.42%+38.98%-78.15% 42.75M
-0.39%-3.54%+22.74%+47.34% 259B
-0.25%-1.39%+5.17%+10.87% 164B
-0.43%-4.24%-19.33%+45.11% 154B
-0.61%-0.22%-56.83%-19.65% 64.27B
-0.24%+2.13%+26.20%+58.50% 61.61B
+0.11%+1.95%+5.31%-10.99% 53.94B
-0.58%-4.08%+19.58%+51.34% 49.04B
+0.11%-1.29%+9.18%+72.50% 48.82B
-0.81%-4.34%+20.64%+71.30% 45.24B
Average -0.38%+1.87%+7.16%+24.82% 90B
Weighted average by Cap. -0.38%+0.57%+4.85%+35.58%

Financials

2026 *2027 *
Net sales 90.09M 81.64M 75.51M 68.13M 128M 8.49B 133M 910M 360M 4.54B 338M 331M 14.4B 94.8M 85.91M 79.46M 71.69M 135M 8.94B 140M 957M 379M 4.78B 356M 348M 15.16B
Net income -9.92M -8.98M -8.31M -7.5M -14.13M -935M -14.63M -100M -39.66M -500M -37.2M -36.42M -1.59B -2.77M -2.51M -2.32M -2.09M -3.94M -261M -4.08M -27.93M -11.06M -139M -10.38M -10.16M -442M
Net Debt - -
Projected Income Statement - Annual - Harvard Bioscience, Inc.
Logo Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Employees
328
Date Price Change Volume
26-11-16 $9.305 -0.91% 11,015
26-11-13 $9.390 +1.90% 18,784
26-11-12 $9.215 -4.80% 15,568
26-11-11 $9.680 +4.54% 105,422
26-11-10 $9.260 +1.87% 88,184
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Harvard Bioscience, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
9.390USD
Average target price
13.00USD
Spread / Average Target
+38.45%
  1. Stock Market
  2. Stocks
  3. HBIO Stock